Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

@article{Brilli2017PrevalenceOH,
  title={Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab},
  author={Lucia Brilli and Riccardo Danielli and Cristina Ciuoli and Luana Calabr{\`o} and Anna Maria Di Giacomo and Alfonso Cerase and Patrizia Paffetti and Fausta Sestini and Brunetta Porcelli and Michele Maio and Furio Pacini},
  journal={Endocrine},
  year={2017},
  volume={58},
  pages={535-541}
}
ObjectiveIpilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4, that has been shown to significantly improve survival in patients with metastatic melanoma. Blocking cytotoxic T-lymphocyte antigen-4 elicits T cell activation, proliferation and anti-tumor response, but can also trigger immune-related adverse events. Among immune-related endocrinopathies, hypophysitis represents the most frequent, with an incidence up to 17% in patients treated with ipilimumab… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Hypophysite induite par les anticorps monoclonaux anti-CTLA-4

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Endocrine side effects induced by immune checkpoint inhibitors.

  • The Journal of clinical endocrinology and metabolism
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

approach and results in patients with pituitary diseases

A. Ricciuti, A. De Remigis, +8 authors Detection of pituitary antibodies by immunofluorescence
  • J. Clin. Endocrinol. Metab. 99, 1758–1766 (2014) Endocrine
  • 2017
VIEW 1 EXCERPT

clinical presentation, treatment, and biological insights

A. Faje, Immunotherapy, hypophysitis
  • Pituitary 19, 82–92
  • 2016
VIEW 2 EXCERPTS

insights into pathogenesis from an autopsy series

P. Caturegli, G. Di Dalmazi, +7 authors Hypophysitis secondary to cytotoxic T-lymphocyte-associated pro blockade
  • Am. J. Pathol. 186, 3225–3235
  • 2016
VIEW 1 EXCERPT

Long - term follow - up of ipilimumab - induced hypophysitis , a common adverse event of the anti - CTLA - 4 antibody in melanoma

C. Gaudy Albarel, F. Castinetti, +4 authors T. Brue
  • Eur . J . Endocrinol .
  • 2015